MANNKIND CORP (MNKD)
Health Care · NASDAQ
MannKind commercializes innovative inhaled insulins, wearable insulin patches, and drug-device infusion systems for diabetes and orphan lung diseases.
What MANNKIND CORP does
MannKind Corporation is a biopharmaceutical company focused on transforming chronic disease care through innovative drug-device combinations and inhaled therapies. The company commercializes three cardiometabolic products: Afrezza (inhaled insulin), Furoscix (subcutaneous furosemide infusion), and V-Go (wearable insulin patch), while also developing treatments for orphan lung diseases including pulmonary hypertension and idiopathic pulmonary fibrosis.
Themes: ["diabetes / cardiometabolic","inhaled therapeutics","pulmonary hypertension and idiopathic pulmonary fibrosis","drug-device combinations","heart failure and fluid overload management","wearable medical devices"]
Fundamentals
- Price$4.14 as of 2026-07-09 close
- Market cap$1.3B as of 2026-07-10
- 1-year return+8.4% as of 2026-07-09 close
- P/E219.57 as of 2026-07-10
- Net margin-6.4% as of 2026-07-10
- Gross margin+78.4% as of 2026-07-10
- ROE-297.7% as of 2026-07-10
- Debt / equity9.95 as of 2026-07-10
- Revenue growth (YoY)+21.2% as of 2026-07-10
- Revenue CAGR (3y)+51.8% SEC XBRL
- Beta1.11 as of 2026-07-10
Key risks (from latest filing)
["Regulatory approval risk: company depends on FDA approval of sBLA for Afrezza in pediatric populations (May 2026 decision) and sNDA for Furoscix ReadyFlow (July 2026 decision)","Commercial execution risk: company is solely responsible for U.S. commercialization of three cardiometabolic products while operating at negative net margins; success depends on market adoption and reimbursement","Partnership and royalty dependence: significant revenue derived from collaborations (e.g., Tyvaso DPI royalties from United Therapeutics) and future milestone payments, creating exposure to partner performance and regulatory outcomes outside direct control"]
Competitors & peers
- Novo Nordisk (NVO)
- Eli Lilly (LLY)
- Sanofi (SNY)
- Tandem Diabetes Care (TNDM)
- United Therapeutics (UTHR)
- Acceleron Pharma / Merck (MRK)
- Genentech / Roche
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.